Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F20%3A00531962" target="_blank" >RIV/68378050:_____/20:00531962 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/20:10416105 RIV/00023736:_____/20:00013044 RIV/00064165:_____/20:10416105

Výsledek na webu

<a href="https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12768" target="_blank" >https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12768</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/1878-0261.12768" target="_blank" >10.1002/1878-0261.12768</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes

Popis výsledku v původním jazyce

Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone marrow (BM). Aging, autoinflammation and autoimmunity are crucial features of disease progression, concordant with promoting growth of malignant clones and accumulation of mutations.Suprabasin(SBSN), a recently proposed proto-oncogene of unknown function, physiologically expressed in stratified epithelia, is associated with poor prognosis of several human malignancies. Here, we showed thatSBSNis expressed in the BM by myeloid cell subpopulations, including myeloid-derived suppressor cells, and is secreted into BM plasma and peripheral blood of MDS patients. The highest expression ofSBSNwas present in a patient group with poor prognosis.SBSNlevels in the BM correlated positively with blast percentage and negatively with CCL2 chemokine levels and lymphocyte count.In vitrotreatment of leukemic cells with interferon-gamma and demethylating agent 5-azacytidine (5-AC) inducedSBSNexpression. This indicated that aberrant cytokine levels in the BM and epigenetic landscape modifications in MDS patients may underlie ectopic expression ofSBSN. Our findings suggest SBSN as a candidate biomarker of high-risk MDS with a possible role in disease progression and therapy resistance.

Název v anglickém jazyce

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes

Popis výsledku anglicky

Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone marrow (BM). Aging, autoinflammation and autoimmunity are crucial features of disease progression, concordant with promoting growth of malignant clones and accumulation of mutations.Suprabasin(SBSN), a recently proposed proto-oncogene of unknown function, physiologically expressed in stratified epithelia, is associated with poor prognosis of several human malignancies. Here, we showed thatSBSNis expressed in the BM by myeloid cell subpopulations, including myeloid-derived suppressor cells, and is secreted into BM plasma and peripheral blood of MDS patients. The highest expression ofSBSNwas present in a patient group with poor prognosis.SBSNlevels in the BM correlated positively with blast percentage and negatively with CCL2 chemokine levels and lymphocyte count.In vitrotreatment of leukemic cells with interferon-gamma and demethylating agent 5-azacytidine (5-AC) inducedSBSNexpression. This indicated that aberrant cytokine levels in the BM and epigenetic landscape modifications in MDS patients may underlie ectopic expression ofSBSN. Our findings suggest SBSN as a candidate biomarker of high-risk MDS with a possible role in disease progression and therapy resistance.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Molecular Oncology

ISSN

1574-7891

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

17

Strana od-do

2403-2419

Kód UT WoS článku

000557864300001

EID výsledku v databázi Scopus

—